Parathyroid tumors have a large clinical and biochemical panel, with primary hyperparathyroidism (PHPT) being the most commonly associated endocrine disturbance, a condition caused by an excessive tumor-related parathormone (PTH) with phenotypes that range from the classical (symptomatic, traditional) form, which is rarely encountered currently, to the more recently defined normocalcemic primary hyperparathyroidism (NPHPT) [1,2]. This evidence concerns the gene PTH and primary hyperparathyroidism.